For domestic PMA postmarket inspections where the District has classified the inspection as No Action Indicated or Voluntary Action Indicated, forward the FACTS coversheet and EIR narrative to the PMA postmarket coordinator via e-mail to the address listed below.
For domestic PMA postmarket inspections where CDRH review is requested or the District has classified the inspection as OAI, and all foreign PMA postmarket inspections, the endorsement coversheet should be labeled as "PMA Postmarket Inspection," include the PMA number that was covered during the inspection, and the FACTS assignment number. Send the EIR, any FDA 483, exhibits, attachments, the firm's responses, and any correspondence issued to the firm to the PMA postmarket coordinator at CDRHPMAPROGRAM@fda.hhs.gov. If the documents related to the PMA postmarket inspection are placed in CMS, an e-mail notification that includes the CMS number should be sent to CDRH's PMA postmarket coordinator. Ensure that the subject line of the e-mail utilizes one of the following nomenclatures: Premarket approval is the process used by FDA to review and evaluate the safety and effectiveness of Class III medical devices. Class III medical devices are those that are lifesupporting or life-sustaining, are for a use that is of substantial importance in preventing impairment of human health, or that present a potential unreasonable risk of illness or injury. 1 All Class III devices (with the exception of certain preamendment Class III devices) must obtain premarket approval from FDA before they can be introduced into interstate commerce. Manufacturers are required to submit a PMA application with substantial evidence that demonstrates the device is safe and effective for the intended use.
Assuring that only safe and effective devices are distributed is a two-phase process.
1. The inherent safety and effectiveness of a device is established during the design phase. A quality system will include proper consideration of such factors as performance requirements, the needs of the user, operational environments, proper selection of components, etc. Assurance that the design will embody the proper degree of safety and effectiveness is obtained through application of an appropriate design and development process requiring design verification and design validation, which includes clinical evaluation and/or laboratory testing.
2.
Once the design has been determined to be safe and effective, the adequacy of the manufacturing process will determine whether the design can be consistently reproduced without degrading this inherent quality. The adequacy of the manufacturing process is established through proper process design and proven through appropriate process validation where applicable. Where deviations from device specifications could occur as a result of the manufacturing process, process control procedures must be established to include procedures for the monitoring and control of the process parameters and component and device characteristics during production.
In a PMA application, manufacturers are required to include descriptions of the methods used in, and the facilities and controls used for, the design, manufacture, processing, packing, storage, and, where appropriate, installation of the device. These requirements for FDA-regulated products are known as current good manufacturing practice (CGMP) requirements, which are promulgated in the Quality System (QS) regulation. The final QS regulation (21 CFR 820) was published in the Federal Register in October 1996 and became effective June 1, 1997. This regulation requires each manufacturer to prepare and implement QS procedures to assure that a formally-established and documented quality system is accomplished. The requirements in this part govern the methods used in, and the facilities and controls used for, the design, manufacture, processing, packing, storage, and, where appropriate, installation of all finished devices intended for human use. The requirements in this part are intended to ensure that finished devices will be safe and effective and otherwise in compliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act). Under the authority of section 515(d)(2)(C) of the FD&C Act, approval of a PMA application for a device can be denied if a manufacturer does not conform to the QS regulation requirements.
B. THE MEDICAL DEVICE REPORTING REGULATION
The . 21 CFR Part 803 requires manufacturers of medical devices, including in vitro diagnostic devices, to report to FDA whenever the manufacturer or importer receives or otherwise becomes aware of information that reasonably suggests that one of its marketed devices:
1. may have caused or contributed to a death or serious injury or, 2. has malfunctioned and the device, or any other device marketed by the manufacturer or importer, would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.
Note: importers (initial distributors) of medical devices are subject to 21 CFR Part 803. In addition, foreign manufacturers whose devices are distributed in the US are also subject to the MDR regulation requirements, per 21 CFR 803.58.
C. THE MEDICAL DEVICE TRACKING REGULATION
Under the authority of section 519(e) of the FD&C Act, the agency may issue a written tracking order that tells a manufacturer to implement a tracking program that meets the requirements of 21 CFR Part 821. Devices subject to tracking may include those that are permanently implanted or life sustaining/life supporting devices that are used outside a device user facility. These devices are considered reasonably likely to cause serious adverse health consequences if they fail. The regulation is intended to ensure that, in the event of a recall or safety alert, a tracked device can be traced by the manufacturer from the device manufacturing facility to the end user or patient.
D. THE CORRECTIONS AND REMOVAL REGULATION
The Corrections and Removal regulation, 21 CFR 806, requires manufacturers and importers to report promptly to FDA any corrections or removals of devices being undertaken to reduce risk to health.
E. THE REGISTRATION AND LISTING REGULATION
The Registration and Listing regulation, 21 CFR 807, requires manufacturers and foreign exporters to register and list their devices; and importers to register.
Note: A complete list of the types of domestic and foreign establishments that must register and list can be found at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/Registra tionandListing/ucm053165.htm. This compliance program provides guidance to FDA field and CDRH staff for Premarket Approval (PMA) preapproval and PMA postmarket inspections and administrative/enforcement activities associated with PMAs. For purposes of this compliance program the term "PMA" will be used for not only the processing of original PMA applications and PMA Supplements, but also other various preapproval applications including: Product Development Protocols (PDP) and Humanitarian Device Exemptions (HDE). In addition, for purposes of this compliance program the term "manufacturer" may also refer to the manufacturer's designated contract manufacturers, sterilizers, and/or relabelers of the PMA device. This is a continuing program, implemented on the basis of directed assignments made to the Field by CDRH.
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PMA Preapproval Inspection
A PMA preapproval inspection is performed to assess a manufacturer's ability to design and manufacture the PMA device in accordance with the conditions specified in the PMA application and the requirements of the Quality System (QS) regulation. Prior to the approval of a PMA application, CDRH will typically issue an inspection assignment for manufacturing sites that are deemed necessary to be inspected. This assignment is issued after the manufacturer has demonstrated in its PMA application that both the design controls and the manufacturing processes and controls have been adequately established.
PMA Postmarket Inspection
A PMA postmarket inspection is typically conducted eight to twelve months after the PMA has been approved. This PMA postmarket inspection provides FDA with the first opportunity to evaluate the newly-approved product since it entered the marketplace. A PMA postmarket inspection also provides FDA with the first opportunity to assess a manufacturer's compliance with the Medical Device Reporting ( 
B. PROGRAM MANAGEMENT INSTRUCTIONS
The following guidelines are suggested for implementing this compliance program:
PMA Preapproval Inspection
The assignment will be issued after the manufacturer has demonstrated in its PMA application that both the design controls and the manufacturing processes have been established. The assignment will identify the device to be covered and will have a specific reporting due date that must be met in order for the Agency to meet statutory deadlines for a decision on the application.
All assignments will be placed in the FDA Field Accomplishments and Compliance Tracking System (FACTS). The District Office or Office of Regulatory Affairs (ORA)/Division of Foreign Field Investigations (DFFI) will be notified electronically of the FACTS assignment number and a copy of the assignment memo will be attached to that e-mail.
The following information will be sent to the appropriate District Office/Investigator once the assignment has been entered into the FACTS database:
a. the PMA manufacturing section, b. inspectional guidance, if any, c.
PMA review memos
For foreign site assignments, all applicable PMA documents will be sent via e-mail to the appropriate investigator as soon as the Office of Compliance (OC)/Field Operations Branch (FOB) is notified that an investigator has been selected and the inspection has been scheduled. The investigator may contact the CDRH reviewer if there are any questions regarding the information provided.
To facilitate communications with the firm on matters pertaining to the status of the inspection, the firm's response to the 483, or the need for a follow-up inspection, the District Office should identify a contact person for each particular PMA inspection assignment. The investigator should give to the firm at the close out of the inspection the name and telephone number of the contact person.
Note: Some PMAs may be granted "Expedited Review" status if the device offers a potential for clinically meaningful benefit as compared to the existing alternatives (preventative, diagnostic, or therapeutic), or when the new medical device promises to provide a revolutionary advance over currently-available alternative modalities. The granting of "Expedited Review" means that the application would receive priority review before other pending PMAs. Therefore, expedited PMA inspection assignments take a top priority when scheduling PMA preapproval inspections.
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PMA Postmarket Inspection
An assignment for a PMA postmarket inspection of manufacturers including contract manufacturers, sterilizers, relabelers, remanufacturers, and/or specification developers will occur approximately eight to twelve months after a PMA or PMA Supplement for new or alternate manufacturing sites has been approved. The assignment will be issued by OC/FOB with an inspection due date range that is between eight to twelve months after PMA approval.
Note: PMA postmarket inspection assignments will not be issued to designated sterilizer firms that meet certain criteria. Refer to Section III.B.3. for further guidance.
All PMA postmarket inspection assignments will be placed in FACTS. The District Office or ORA/DFFI will be notified electronically of the FACTS assignment number and a copy of the assignment memo will be attached to that e-mail.
Once an investigator has been selected and the inspection has been scheduled, the District Office or ORA/DFFI should notify via e-mail the PMA postmarket coordinator at CDRHPMAPROGRAM@fda.hhs.gov, identifying the investigator that will be conducting the inspection and the start date of the inspection. Copies of any cover letters for any PMA supplements submitted by the firm since the PMA was approved will be sent to the investigator electronically for review prior to the inspection.
The postmarket inspection should assure that the manufacturer of an approved PMA device: Before initiating the premarket approval inspection, the investigator should review the manufacturing section of the PMA application and any other documents provided by Office of Compliance (OC)/Field Operations Branch (FOB) in preparation for the inspection. It is important to ensure that a manufacturer has completed all process validation activities at the time of the inspection. Refer to Section B for further instructions regarding process validation activities.
Inspectional time for the PMA preapproval inspection should be reported under PAC 83001; however, if the inspection also includes coverage of other areas, divide the inspectional hours between the relevant PAC codes, as appropriate.
b. PMA Postmarket Inspection
The PMA postmarket inspection will assess the firm's systems, methods, and procedures for the specific devices to ensure that the firm's quality management system is effectively established (defined, documented, and implemented) and effectively maintained. The PMA postmarket inspection should also confirm that commitments made by the firm at the time the applications were approved have been completed or are underway in accordance with those commitments.
Inadequately-controlled changes to a newly-marketed device often lead to complaints and/or service repairs as indicators of performance problems, as well as additional changes in the design, manufacturing process, and/or quality assurance systems relative to the PMA device. Therefore, there should be a focus on these areas to ensure that there are no indications of potential performance problems. The PMA postmarket inspection includes the assessment of postmarket information on the specific PMA devices covered during the inspection and should include: The PMA postmarket inspection can be conducted as a Level 1 (Abbreviated), or Level 2 (Comprehensive) inspection. Regardless of the type of inspection that is conducted, all applicable satellite systems must be covered during the PMA postmarket inspection, as these areas are not covered during a PMA preapproval inspection. For Level 1 inspections, the selection to cover either the P&PC subsystem or the Design Controls subsystem should be determined based upon the review of postmarket information (conducted prior to the inspection), subsystems that were covered during any previous inspection, and any other indicators such as design or manufacturing changes. Refer to Part III of CP 7382.845, "Inspection of Medical Device Manufacturers," for further guidance on Level 1 and Level 2 inspections.
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Inspectional time for the PMA postmarket inspection should be reported under PAC 83001A; however if the inspection also includes coverage of other areas, divide the inspectional hours between the relevant PAC codes, as appropriate.
Inspectional Instructions a. Required Statements
The following statement should be included on each FDA 483:
This document lists observations made by the FDA representatives during the inspection of your facility. They are inspectional observations and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective actions in response to an observation, you may discuss the objection or action with FDA representatives during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.
For all medical device inspections, the FDA 483 should contain the following additional statement:
The observations noted in this form FDA 483 are not an exhaustive listing of objectionable conditions. Under the law, your firm is responsible for conducting internal self audits to identify and correct any and all violations of the quality system requirements.
b. Satellite Program Areas
Refer to Part III of CP 7382.845, "Inspection of Medical Device Manufacturers," for a discussion of coverage of satellite program areas including MDRs, Corrections & Removals, Tracking, and Sterilization.
At the time of the PMA application, a manufacturer may not have completed all of the required process validations and, therefore, CDRH may not have conducted a review of this data. It is expected that at the time of the inspection, the manufacturer will have completed validations of all processes requiring validation. Therefore, implementation of the process validation activities should be focused on during the inspection, as a thorough review of completed process validations may not have been conducted by CDRH during the review of the PMA application.
If it is identified during the inspection that process validation activities have not been successfully completed by the manufacturer, the investigator should conclude the inspection. Refer to Part V, Section A for further guidance on regulatory/administrative follow up.
Special Instructions Concerning Design Controls
Investigators should ensure that the design and development activities for the PMA devices are sufficiently covered during an inspection. In some cases, one facility may not cover all activities related to the PMA devices. There are a number of multi-establishment firms that conduct all design activities at a single facility (sometimes referred to as a research and development (R&D) center or a corporate design facility). If the establishment scheduled for inspection is serviced by an R&D center or a corporate facility, review the establishment jacket, before beginning the inspection, consult the agency's on-line OEI databases and/or directly contact the district involved. For PMA preapproval inspections, the R&D center or the corporate design facility should be inspected regardless of the facility's inspectional history. For PMA postmarket inspections, determine if the home district of the R&D center or the corporate design facility has conducted a design control inspection of that facility within the previous two years. If such an inspection was conducted, it will not be necessary to conduct a design control assessment at the establishment scheduled for inspection. If an inspection was not conducted within the previous two years, issue an assignment to the home district of the R&D center or the corporate design facility requesting a design control inspection for the devices listed in the PMA postmarket inspection assignment.
Some manufacturers may have their PMA devices designed under contract. These manufacturers must comply with the requirements for using contractors or service suppliers under 21 CFR 820.50 as well as ensure compliance with 21 CFR 820.30. The manufacturer must maintain or have readily accessibility copies of a Design History File for any PMA devices that are in production.
Observations relating to design controls placed on the Form FDA 483 should be limited to the If the firm has made significant design or manufacturing changes to the PMA device that require the submission of a PMA supplement, the investigator should attempt to get CDRH/OC and/or OIVD concurrence during the inspection before placing the observation on the Form FDA 483. When CDRH concurrence cannot be obtained before the completion of the inspection, the observation should not be placed on the Form FDA 483. Investigators should discuss the issue in the EIR, collect complete documentation, and submit the documentation to CDRH for further review.
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Special Instructions for Sterilization Processes
Sterilization processes for PMA devices may be conducted at the device manufacturer or a contract sterilizer. Inspectional coverage of the sterilization process should follow the Sterilization Process Controls section found in the QSIT Guide. Sterilization processes are covered as a sub-part of the Production and Process Controls subsystem under QSIT. The instructions for inspecting sterilization processes are applicable at the following types of facilities:
 device manufacturers that sterilize their own product,  device manufacturers that use contract sterilizers, and  contract sterilizers Note: The portion of the inspection spent covering sterilization processes should be reported under PAC 82845S.
Refer to Part III, A.6, of CP 7382.845 "Inspection of Medical Device Manufacturers," for guidance on collection of samples relating to sterilization issues.
Many contract sterilizers have a significant number of customers who manufacture PMA devices. Therefore, inspectional assignments for PMA postmarket contract sterilizers may not be issued for each PMA product if the facility meets the following criteria:
1. The facility was inspected during the previous two years, 2. The facility was found to be in compliance with the Quality System regulation; and, 3. The same sterilization method was covered as the one identified in the PMA.
For domestic contract sterilizers, an e-mail will be sent from OC/FOB to the district office requesting confirmation that the criteria outlined above has been met and an inspection is not necessary.
PMA postmarket inspection assignments for contract sterilizers will still occur in situations where the above criteria were not met or in the following situations where:
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1. Changes in the sterilization process cannot be clarified or checked by reviewing sterilization records at the finished device manufacturer; 2. Information obtained from the manufacturer discloses a possible problem at the contract sterilizer; and/or, 3. Information needs to be verified.
Note: The inspectional policy/strategy described above is only applicable to PMA postmarket inspections of contract sterilizers. CDRH/OC will continue to issue PMA preapproval inspection assignments for contract sterilizers. 
FDA Field Accomplishments and Compliance Tracking System (FACTS)
a. When selecting specific manufacturing processes for the PMA devices to represent profile classes, investigators should give preference to:
 CAPA indicators of process problems,  processes used to manufacture high-risk components and, subassemblies, as called out in the definition of the term "product" in 21 CFR 820.3(r),  processes that have a high risk of causing medical device failure,  processes that require process validation,  processes that are new to the manufacturer,  processes that cover a variety of process technologies and profile classes,  common processes used in multiple products, and  processes not covered during previous inspections.
In cases where it has been determined that the QS deficiencies meet the criteria of Situation I, as outlined in Part V of CP 7382.845, "Inspection of Medical Device Manufacturers,"," FDA has the authority to withhold approval of the PMA application for that particular device. Therefore, the District should recommend withholding approval when the inspection identifies QS deficiencies that meet the criteria for Situation I, even though the District is not prepared to seek regulatory action because the deficiencies do not extend to other devices manufactured in the facility. Some significant QS deviation examples from Part V include, but are not limited to:
 Total failure to define, document, or implement a quality system or one of the seven subsystems, such as failing to complete any required validations of full-scale production processes for the specific device covered by the pending original PMA application, or no procedures that address corrective and preventive actions.
 A deficiency in one or more elements of the subsystems. The QSIT Guide can be utilized to provide guidance in determining what are considered to be "major" problems if not adequately addressed.  Non-correction of major deficiencies from previous inspections.
If the criteria of Situation I is met, CDRH will issue a PMA Official Action Indicated (OAI) Letter to the device manufacturer outlining the deficiencies identified during the inspection. The PMA will remain on hold and approval of the application will be pending resolution of QS deficiencies and often a re-inspection.
When the PMA preapproval inspection is conducted in conjunction with another type of inspection that involves commercially-marketed devices, and the deviations extend beyond the scope of the PMA device to other devices manufactured in the facility, then the PMA application may be withheld and regulatory and/or administrative actions may be taken against the commercially-marketed devices to assure that the deviations are corrected. If legal action is not immediately warranted, a Warning Letter may be issued for only the commercially-marketed devices. Issuance of all Warning Letters should follow Chapter 4 of the Regulatory Procedures Manual (RPM), http://www.fda.gov/ora/compliance_ref/rpm/. A separate PMA OAI letter may also be issued to the firm outlining the deviations related to the PMA devices. In such cases, a copy of the Warning Letter should be sent to the PMA preapproval coordinator in support of the District's recommendation to delay or withhold approval or the PMA application. It is important that before any Warning Letter is issued that CDRH also performs a QS Review of the EIR for the PMA aspect in order to ensure a uniform and consistent message between these two communications to the medical device manufacturer.
b. Situation II
In cases where it has been determined that the inspection meets the criteria of Situation II, as outlined in Part V of CP 7382.845, "Inspection of Medical Device Manufacturers,"," and deviations have been identified, CDRH will issue a PMA Voluntary Action Indicated (VAI) letter to the device manufacturer outlining the deficiencies noted during the inspection.
Note: Districts should not recommend withholding the PMA application for inspections that meet the criteria of Situation II.
B. PMA POSTMARKET INSPECTIONS
The determinations for Situation I or Situation II and any regulatory/administrative follow-up actions for PMA postmarket inspections should follow the guidelines discussed in Part V of CP 7382.845, "Inspection of Medical Device Manufacturers."
Quality System Regulatory/Administrative Follow-Up
Refer to Part V of CP 7382.845, "Inspection of Medical Device Manufacturers," for a discussion of regulatory and administrative follow-up actions for QS deficiencies. 
